Phase I trial of poly-L-glutamate camptothecin (CT-2106) administered weekly in patients with advanced solid malignancies

Clinical Cancer Research

Volumn 13, Issue 19, 2007, Pages 5855-5861

  Homsi, Jade ^a   Simon, George R ^a   Garrett, Chris R ^a   Springett, Gregory ^a   De Conti, Ronald ^a   Chiappori, Alberto A ^a   Munster, Pamela N ^a   Burton, Michelle K ^a   Stromatt, Scott ^b   Allievi, Claudia ^b   Angiuli, Patrizia ^b   Eisenfeld, Amy ^b   Sullivan, Daniel M ^a   Daud, Adil I ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b Cell Therapeutics Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAMPTOTHECIN; CAMPTOTHECIN DERIVATIVE; CT 2106; GRANISETRON; IFOSFAMIDE; LORAZEPAM; POLYGLUTAMIC ACID PLUS CAMPTOTHECIN; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; AREA UNDER THE CURVE; ARTICLE; BLOOD TOXICITY; BREAST CANCER; CLINICAL ARTICLE; CLINICAL TRIAL; COLON CANCER; CONTROLLED STUDY; DIARRHEA; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE ESCALATION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MEGADOSE; DRUG URINE LEVEL; FATIGUE; FEMALE; FLUORESCENCE; HEMATURIA; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HISTIOCYTOMA; HUMAN; LUNG CANCER; LYMPHOCYTOPENIA; MALE; MAXIMUM TOLERATED DOSE; MELANOMA; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OSTEOSARCOMA; PANCREAS CANCER; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; RETCHING; SARCOMA; SIDE EFFECT; SOLID TUMOR; SQUAMOUS CELL CARCINOMA; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; URINARY FREQUENCY; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CAMPTOTHECIN; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; LACTONES; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASMS; POLYGLUTAMIC ACID; SOLUBILITY; TIME FACTORS;

EID: 35348868039     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-06-2821     Document Type: Article

References (40)

1. Burris HA, Rothenberg ML, Kuhn JG, Von Hoff DD. Clinical trials with the topoisomerase I inhibitors. Semin Oncol 1992;19:663-9.
2. Rothenberg ML. Topoisomerase I inhibitors: review and update. Ann Oncol 1997;8:837-55.
3. Chourpa I, Millot JM, Sockalingum GD, Riou JF, Manfait M. Kinetics of lactone hydrolysis in antitumor drugs of camptothecin series as studied by fluorescence spectroscopy. Biochim Biophys Acta 1998;1379:353-66.
4. Mi Z, Malak H, Burke TG. Reduced albumin binding promotes the stability and activity of topotecan in human blood. Biochemistry 1995;34:13722-8.
5. Rothenberg ML, Blanke CD. Topoisomerase I inhibitors in the treatment of colorectal cancer. Semin Oncol 1999;26:632-9.
6. Creaven PJ, Allen LM, Muggia FM. Plasma camptothecin (NSC-100880) levels during a 5-day course of treatment: relation to dose and toxicity. Cancer Chemother Rep 1972;56:573-8.
7. Muggia FM, Creaven PJ, Hansen HH, Cohen MH, Selawry OS. Phase I clinical trial of weekly and daily treatment with camptothecin (NSC-100880): correlation with preclinical studies. Cancer Chemother Rep 1972;56:515-21.
8. Li C. Poly(L-glutamic acid)-anticancer drug conjugates. Adv Drug Deliv Rev 2002;54:695-713.
9. Singer JW, De Vries P, Bhatt R, et al. Conjugation of camptothecins to poly-(L-glutamic acid). Ann N Y Acad Sci 2000;922:136-50.
10. Springett GM, Takimoto C, McNamara M, et al. Phase I study of CT-2106 (polyglutamate camptothecihn) in patients with advanced malignancies. J Clin Oncol 2006;22:3127.
11. Sparreboom A, Zamboni WC. Topoisomerase I-targeting drugs. In: Chabner BA, Longo DL, editors. Cancer chemotherapy and biotherapy. 4th ed. Philadelphia: Lippincott Williams; 2005. p. 371-413.
12. Pommier Y. Topoisomerase I inhibitors: camptothecins and beyond. Nat Rev Cancer 2006;6:789-802.
13. Liu LF, Desai SD, Li TK, et al. Mechanisms of action of camptothecin. Vol. 922. New York: Ann N Y Acad Sci; 2000. p. 1-10.
14. Hertzberg RP, Caranfa MJ, Hecht SM. On the mechanism of topoisomerase I inhibition by camptothecin: evidence for binding to an enzyme-DNA complex. Biochemistry 1989;28:4629-38.
15. Scott DO, Bindra DS, Stella VJ. Plasma pharmacokinetics of lactone and carboxylate forms of 20(S)-camptothecin in anesthetized rats. Pharm Res 1993;10:1451-7.
16. Burke TG, Mi Z. The structural basis of camptothecin interactions with human serum albumin: impact on drug stability. J Med Chem 1994;37:40-6.
17. Moertel CG, Schutt AJ, Reitemeier RJ, Hahn RG. Phase II study of camptothecin (NSC-100880) in the treatment of advanced gastrointestinal cancer. Cancer Chemother Rep 1972;56:95-101.
18. Gottlieb JA, Guarino AM, Call JB, Oliverio VT, Block JB. Preliminary pharmacologic and clinical evaluation of camptothecin sodium (NSC-100880). Cancer Chemother Rep 1970;54:461-70.
19. Kehrer DF, Soepenberg O, Loos WJ, Verweij J, Sparreboom A. Modulation of camptothecin analogs in the treatment of cancer: a review. Anticancer Drugs 2001;12:89-105.
20. Pizzolato JF, Saltz LB. The camptothecins. Lancet 2003;361:2235-42.
21. Rowinsky EK, Grochow LB, Ettinger DS, et al. Phase I and pharmacological study of the novel topoisomerase I inhibitor 7-ethyl-10-[4-(1-piperidino)-1- piperidino]carbonyloxycamptothecin (CPT-11) administered as a ninety-minute infusion every 3 weeks. Cancer Res 1994;54:427-36.
22. O'Leary J, Muggia FM. Camptothecins: a review of their development and schedules of administration. Eur J Cancer 1998;34:1500-8.
23. Garcia-Carbonero R, Supko JG. Current perspectives on the clinical experience, pharmacology, and continued development of the camptothecins. Clin Cancer Res 2002;8:641-61.
24. Zamai M, VandeVen M, Farao M, et al. Camptothecin poly[N-(2- hydroxypropyl) methacrylamide] copolymers in antitopoisomerase-I tumor therapy: intratumor release and antitumor efficacy. Mol Cancer Ther 2003;2:29-40.
25. Singer JW, Bhatt R, Tulinsky J, et al. Water-soluble poly-(L- glutamic acid)-Gly-camptothecin conjugates enhance camptothecin stability and efficacy in vivo. J Control Release 2001;74:243-7.
26. Schoemaker NE, van Kesteren C, Rosing H, et al. A phase I and pharmacokinetic study of MAG-CPT, a water-soluble polymer conjugate of camptothecin. Br J Cancer 2002;87:608-14.
27. Schluep T, Cheng J, Khin KT, Davis ME. Pharmacokinetics and biodistribution of the camptothecin-polymer conjugate IT-101 in rats and tumor-bearing mice. Cancer Chemother Pharmacol 2006;57:654-62.
28. Rowinsky EK, Rizzo J, Ochoa L, et al. A phase I and pharmacokinetic study of pegylated camptothecin as a 1-hour infusion every 3 weeks in patients with advanced solid malignancies. J Clin Oncol 2003;21:148-57.
29. Paranjpe PV, Stein S, Sinko PJ. Tumor-targeted and activated bioconjugates for improved camptothecin delivery. Anticancer Drugs 2005;16:763-75.
30. Minko T, Paranjpe PV, Qiu B, et al. Enhancing the anticancer efficacy of camptothecin using biotinylated poly(ethylene glycol) conjugates in sensitive and multidrug-resistant human ovarian carcinoma cells. Cancer Chemother Pharmacol 2002;50:143-50.
31. Harada M, Sakakibara H, Yano T, Suzuki T, Okuno S. Determinants for the drug release fromT-0128, camptothecin analogue-carboxymethyl dextran conjugate. J Control Release 2000;69:399-412.
32. Guiotto A, Canevari M, Orsolini P, et al. Synthesis, characterization, and preliminary in vivo tests of new poly(ethylene glycol) conjugates of the antitumor agent 10-amino-7-ethylcamptothecin. J Med Chem 2004;47:1280-9.
33. Fleming AB, Haverstick K, Saltzman WM. In vitro cytotoxicity and in vivo distribution after direct delivery of PEG-camptothecin conjugates to the rat brain. Bioconjug Chem 2004;15:1364-75.
34. Dharap SS, Qiu B, Williams GC, et al. Molecular targeting of drug delivery systems to ovarian cancer by BH3 and LHRH peptides. J Control Release 2003;91:61-73.
35. Conover CD, Greenwald RB, Pendri A, Shum KL. Camptothecin delivery systems: the utility of amino acid spacers for the conjugation of camptothecin with polyethylene glycol to create prodrugs. Anticancer Drug Des 1999;14:499-506.
36. Cheng J, Khin KT, Jensen GS, Liu A, Davis ME. Synthesis of linear, β-cyclodextrin-based polymers and their camptothecin conjugates. Bioconjug Chem 2003;14:1007-17.
37. Cheng J, Khin KT, Davis ME. Antitumor activity of β-cyclodextrin polymer-camptothecin conjugates. Mol Pharm 2004;1:183-93.
38. Caiolfa VR, Zamai M, Fiorino A, et al. Polymer-bound camptothecin: initial biodistribution and antitumour activity studies. J Control Release 2000;65:105-19.
39. Maeda H, Matsumura Y. Tumoritropic and lymphotropic principles of macromolecular drugs. Crit Rev Ther Drug Carrier Syst 1989;6:193-210.
40. Maeda H, Wu J, Sawa T, Matsumura Y, Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release 2000;65:271-84.